医科达直线加速器多叶准直器(MLC)故障分析与检修

医用直线加速器是治疗恶性肿瘤的主要设备.随着放射治疗技术水平的日益提高,越来越多的医用直线加速器配备了多叶准直器(Multileaf Collimator,MLC)系统以便能更好地产生适形射野轮廓、完成放射治疗.现对医用直线加速器多叶准直器3例常出现的故障作出分析,以供参考.     

医用直线加速器的设备维护及治疗安全

为了确保医用直线加速器安全可靠的使用,各项指标达到有关放射治疗质量保证和质量控制的要求,减少故障发生率,提高医用加速器使用的质量控制及治疗效果,本文总结了医用直线加速器的设备维护方法与治疗安全注意事项.     

医用电子直线加速器选购中应注意的几个问题

医用电子直线加速器是肿瘤放射治疗的主要设备之一,它可以产生电子线和X线两种模式的治疗束,每种治疗束又可分为不同的能量挡,除了用于常规放射治疗外,越来越多地应用于进行各种精确放射治疗.本文根据作者的经验,从选购论证加速器关键部件性能和售后服务等方面介绍在选择医用电子直线加速器时应注意的问题.     

西门子直线加速器不出射线故障维修

医用直线加速器是大型放射治疗设备,西门子加速器结构较为复杂,且数字化程度高,在放射治疗中出现剂量联锁后导致停机而中断治疗。因此医院使用的西门子加速器的维修和保养显得尤为重要。     

国外医用直线加速器的进展

医用直线加速器是目前最主要的放射治疗设备之一,本文从加速器核心部件、能量和剂量特性、计算机控制系统、电子射野影像系统等方面介绍国外加速器技术的新进展.     

基层医院医科达Precise直线加速器故障分析及维修的相关分析

医科达Precise医用直线加速器属于临床常用的医疗器械之一,常被临床用于患者的放射治疗中,但临床发现,该类医疗器械常易出现故障,为不影响患者接受放射治疗,有必要对Precise医用直线加速器的故障现象及其发生原因进行分析,并及时给予维修。本文将对医科达Precise医用直线加速器的常见故障现象进行分析,并提出相关的维修方案。     

GK-06-100医用直线加速器输出剂量的测量及校准

医用直线加速器的各项参数随着机器的运行和外界条件的变化会发生一些改变,所以要定期对其进行测量及校准,以保证放射治疗计划准确有效地实施.现将我院根据IAEA277规程对GK-06-100医用直线加速器输出剂量进行测量及校准报告如下.     

太原市某医院医用直线加速器性能检测与防护分析

<正>医用加速器已经普遍应用于全国各大医院进行临床肿瘤的放射治疗,因此,对医用电子直线加速器放射治疗机的主要性能指标进行质量控制和放射防护的检测和研究都是非常必要的。加速器设备性能检测和防护检测是一个复杂而且技术要求较高的工作,它不仅是辐射危害得以有效控制的一项重要措施,也是放射卫生工作的一项重要内容。本单位对太原市某医院的一台医用直线加速器进行性能和放射防护检测。1资料与方法1.1加速器性能检测:使用绝对剂量仪Dose1、Dineutron型     

医用直线加速器的研究进展

本文简介了医用直线加速器的发展情况，重点介绍了常规放射治疗设备（Conventional radiation therap）的特点，3D适形放射治疗设备（3-dimensional conformal），3D适形调强放射治疗设备（3D Oonforma]and Intensity Modulation—IMRT），还有图像引导设备（Image Guide Radio Therapy—IGRT）的研究现状，最后指出医用直线加速器的发展方向。     

Varian2100C/D加速器GFIL连锁故障的检修

美国瓦里安公司生产的Clinac 2100C/D曾是世界上最多的用于放射治疗的医用电子直线加速器,在国内很多医院拥有该类型的加速器以及由其发展而来的Clinae C系列医用电子加速器."GFIL"连锁故障是其常见故障,本文简单介绍Varian2100C/D加速器GFIL连锁故障的分析及排除方法.     

Analytical Quality,Test Quality and Quality Costs

This paper discusses briefly analytical quality and its determinants design of quality assurance procedures on the basis of quality specifications and quality-cost models test quality and medical costs external quality assessment and harmonization of clinical chemical test results the potential role of computers, database and knowledge-based systems in achieving quality goals in decentralized analytical activities.     

PACS系统的质量保证与质量控制

以保证高质量影像图像以及控制受检者和放射从业人员辐射剂量为宗旨的QA、QC工作,将是医学信息界的一个重要课题.自动化、数字化可以减少一些问题,但可能引起新的问题的发生,探索出一套行之有效的查错、纠错及消除错误的方法及措施,是PACS质保/质控工作须完成的任务.     

放射治疗中的质量保证与质量控制

本文通过对内蒙地区24家放疗单位的调查,结合实际工作指出要做好放射治疗中的QA和QC2工作;首先要建立起完善的QA与QC保证体系,同时要完善设备配置,不断提高工作人员业务技能.     

Quality Specifications

By means of an accurate immunoenzymatic assay, the prevalence was studied of antibodies to hepatitis C virus (HCV) in three different populations: 74 patients affected with hepatocellular carcinoma (HCC) on preexisting cirrhosis, 82 patients with liver cirrhosis but with no apparent neoplasm, and 70 control subjects, hospitalized for various conditions, of internal medicine or geriatric interest. 70.2% of HCC patients exhibited anti-HBC antibodies, versus 47.5% of cirrhotic subjects with no tumor and 7.1% of controls. Such results suggest the possible role of HCV in the etiopathogenesis of HCC, and its possible synergy with other agents - e.g., hepatitis B virus, alcohol - in causing chronically injured hepatocytes to become neoplastic.     

Analytical Quality

Objectives. To evaluate the long term total imprecision of HbA1c testing within the county of Uppsala in relation to the Swedish analytical goal of coefficient of variation (CV) &;lt;3% for HbA1c and to study the cost of an external quality assurance program for point-of-care HbA1c The county uses Bayer DCA 2000TM for point-of care HbA1c testing currently having 23 of these instruments.

Methods. Method imprecision was assessed by analysis of patient samples performed as split samples during a 3 year period (2002-2004) as part of the quality assurance program for point-of-care HbA1c testing. The samples were first analysed on a Bayer DCA 2000TM and the samples were then sent to the centralised laboratory for reanalysis with an HPLC system (Variant IITM, Biorad). The testing was performed approximately 8 times per year with each instrument.

Results. The median CV between the HPLC method and the point-of-care instruments for each unit was slightly higher than 3%.

Conclusion. The DCA 2000TM systems have an acceptable imprecision and agreement with the central laboratory. The test results show acceptable agreements within the county regardless where the patient is tested. The cost of the external quality assurance program is calculated to be approximately SEK 1340 (Euro 150) per instrument.